Clinical Trial Update: A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate the efficacy and safety of imatinib mesylate in patients with unresectable or metastatic gastrointestinal stromal tumors expressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Status: COMPLETED | Results posted: 2014-07-15